FibroGen (FGEN)
(Delayed Data from NSDQ)
$0.36 USD
+0.02 (6.02%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.36 0.00 (0.76%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.36 USD
+0.02 (6.02%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.36 0.00 (0.76%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum C VGM
Zacks News
Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akebia Expands Vadadustat Licensing Deal With Vifor Pharma
by Zacks Equity Research
Akebia Therapeutics (AKBA) and Vifor Pharma expand licensing agreement related to commercialization of Akeba's pipeline candidate, vadadustat, to include additional dialysis organizations.
Options Traders Expect Huge Moves in FibroGen (FGEN) Stock
by Zacks Equity Research
FibroGen (FGEN) needs investors to pay close attention to the stock based on moves in the options market lately.
What's in the Cards for Corbus (CRBP) This Earnings Season?
by Zacks Equity Research
Corbus (CRBP) is expected to provide updates on its pipeline candidates in the fourth quarter conference call.
What's in Store for Teladoc's (TDOC) Q4 Earnings?
by Zacks Equity Research
Teladoc's (TDOC) Q4 earnings might suffer high expenses, partly offset by rise in revenues.
Tenet Healthcare (THC) Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Tenet Healthcare's (THC) Q4 earnings are likely to suffer lower admissions due to divestitures.
FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of -42.86% and -37.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Cronos (CRON) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates when Cronos (CRON) reports third-quarter results.
What's in the Cards for BioSpecifics (BSTC) in Q3 Earnings?
by Zacks Equity Research
On BioSpecifics' (BSTC) Q3 conference call, investor focus will be on its progress with the development of CCH for treating uterine fibroids.
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 51.72% and 53.14%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in FibroGen (FGEN): Stock Soars 48.2%
by Zacks Equity Research
FibroGen (FGEN) was a big mover last session, as the company saw its shares rise over 48% on the day amid huge volumes.
Why Did FibroGen (FGEN) Stock Hit All-Time High Today?
by Benjamin Rains
Shares of FibroGen (FGEN) skyrocketed on Tuesday after the biotech company reported strong results in its most recent series of tests for its new drug that is set to help treat a fatal lung disease.
Should You Buy FibroGen (FGEN) Ahead of Earnings?
by Zacks Equity Research
Investors are always looking for stocks that are poised to beat at earnings season and FibroGen, Inc. (FGEN) may be one such company.
Mylan (MYL) Q1 Earnings: Will the Stock Pull a Surprise?
by Zacks Equity Research
Mylan N.V. (MYL) is scheduled to report first-quarter 2017 results on May 10, before the market opens.
What's in the Cards for Repros (RPRX) this Earnings Season?
by Zacks Equity Research
Repros Therapeutics Inc. (RPRX) is expected to report first-quarter 2017 results this month. Let's see how things are shaping up for this quarter.
Should You Sell FibroGen, Inc (FGEN) Before Earnings?
by Zacks Equity Research
FibroGen, Inc (FGEN) stock looks lucrative Before Earnings on the back of its solid zacks rank and positive earnings ESP.
Is Endo (ENDP) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Endo International plc (ENDP) is scheduled to report first-quarter 2017 results on May 9, before the opening bell.
Is Horizon Pharma (HZNP) Poised for a Beat in Q1 Earnings?
by Zacks Equity Research
Horizon Pharma plc (HZNP) is scheduled to report first-quarter 2017 results before the opening bell on May 8.
What's in the Cards for Allergan (AGN) this Earnings Season?
by Zacks Equity Research
Allergan plc (AGN) will be reporting first-quarter 2017 earnings result on May 9, before the market opens.
Arena Pharmaceuticals (ARNA) Q1 Earnings: What's in Store?
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) is expected to report first-quarter 2017 on May 9, after market closes.
Can Ligand (LGND) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report first-quarter 2017 results on May 9, after the market closes.
What's in Store for Mallinckrodt (MNK) This Earnings Season?
by Zacks Equity Research
Mallinckrodt plc (MNK) is set to report first-quarter fiscal 2017 results on May 8.
What to Expect from Epizyme (EPZM) This Earnings Season?
by Zacks Equity Research
Epizyme, Inc. (EPZM) is scheduled to report first-quarter 2017 results on May 8, before the opening bell.
What's in Store for Adverum (ADVM) in Q1 Earnings?
by Zacks Equity Research
Adverum Biotechnologies, Inc (ADVM) is expected to report first-quarter 2017 results later this month.
What's in the Cards for Inovio (INO) This Earnings Season?
by Zacks Equity Research
Inovio Pharmaceuticals, Inc. (INO) is scheduled to report first-quarter 2017 results, after market closes. The company incurred wider-than-expected loss in the last quarter.